← board
SGMT
Sagimet Biosciences Inc.distress 2/10 · well-funded / low risk$6.98-1%today-32% from 52w high
Metabolic / Obesity 1
Lead: acne · target THR-β
Revenue
pre-revenue
Liquidity
$105M
Runway
2.6 yrs
Shares 1y
+44%
Price & events
+9.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-8.8%
1W
-1.1%
1M
+18.9%
3M
+13.7%
6M
-27.2%
1Y
+113.5%
2Y
—
5Y
-56.2%
All
Overview
- Market Cap
- $214.11M
- Volume
- 102.99K
- 52 Week Range
- $4.55 – $10.24
- Total Shares
- 30.67M
- Float Shares
- 59.14M
- Short %
- 13.60%
- % Held by Insiders
- 3.50%
- % Held by Institutions
- 21.93%
- RVOL
- 0.08x
- Beta
- 3.38
Pipeline stages · 1 programs
denifanstat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 3 | denifanstatbreakthrough | MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver | 0 | withdrawn |
| 2025-10-20 | Phase 1 | Denifanstat, Resmetirombreakthrough | Healthy | 40 | completed |
Catalyst news & presentations · 16
- second half of 2026Guided 55%trial initiationsecondaryPhase 2denifanstat plus resmetirom · Phase 2 proof-of-concept trial initiationSEC 8-K
- 2H 2026Guided 55%trial initiationsecondaryPhase 2TVB-3567 · Phase 2 proof of concept clinical trial anticipated to beginSEC 8-K
- 2026Guided 40%readoutPhase 1TVB-3567 · Phase 1 clinical trial results anticipatedSEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 1denifanstat · Data readout from Phase 1 PK trial of denifanstat and resmetiromSEC 8-K
- 2025-12-31partnershipdenifanstat plus resmetirom · Entered global exclusive license with TAPI for innovative resmetirom API formsSEC 8-K
- by the end of 2025readoutPhase 1denifanstat + resmetirom · Topline data from Phase 1 PK trial of denifanstat and resmetirom combination.SEC 8-K
- second half of 2025trial initiationsecondaryPhase 1denifanstat · Phase 1 PK trial of denifanstat and resmetiromSEC 8-K
- 2025trial initiationsecondaryPhase 1TVB-3567 · First-in-human Phase 1 trial initiation planned in 2025.SEC 8-K
- 2025-10-01fda agreementdenifanstat · Ascletis completed pre-NDA consultation with China NMPA.SEC 8-K
- 2Q2025readoutPhase 3denifanstat · Topline results from Phase 3 acne trialSEC 8-K
- June 2025trial initiationsecondaryPhase 1TVB-3567 · First-in-human Phase 1 trial of TVB-3567 initiated in the U.S.SEC 8-K
- 1Q2025trial initiationsecondaryPhase 3denifanstat · first patient anticipated 1Q2025SEC 8-K
- 1Q2025trial initiationsecondaryPhase 3denifanstat · First patient dosed in Phase 3 MASH trialSEC 8-K
- 2025-03-11fda agreementTVB-3567 · FDA cleared IND for TVB-3567 for acneSEC 8-K
- second half of 2024trial initiationsecondaryPhase 3denifanstat · Phase 3 program initiation for denifanstat in MASH pending FDA feedback.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $26 (+275% upside) · 10 analysts
- 2026-05-19CitizensMarket Outperform
- 2026-05-04Canaccord GenuityBuy
- 2026-04-29GuggenheimBuy
- 2026-03-11HC Wainwright & Co.Buy
- 2026-02-03GuggenheimBuy
- 2026-02-03HC Wainwright & Co.Buy
Competitors — THR-β
- none identified
Recent news
- 2026-07-22Insider Sell: George Kemble Sells Shares of Sagimet Biosciences Inc (SGMT) - GuruFocus
- 2026-07-22Sagimet Biosciences officer Rozek sells $81,832 in shares By Investing.com - Investing.com Nigeria
- 2026-07-22Form 4 Sagimet Biosciences Inc For: 22 July By Investing.com - Investing.com Canada
- 2026-07-22Sagimet Biosciences CEO David Happel disposes of $497,067 in shares - Investing.com
- 2026-07-21Sagimet to advance denifanstat Phase 3 in US; $104.5M cash, $175M offering funds operations through 2028 - TradingView
- 2026-07-20Sagimet Biosciences Inc. SEC Filing (Jul 20, 2026) - Stock Titan
- 2026-07-20Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A – MUN:0O2 - TradingView
- 2026-07-16Sagimet (SGMT) Has Fresh Index Visibility, but the Real Test Is Still Denifanstat Execution - AlphaStreet
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.